Key Highlights
•
UK experts have released new safety-focused recommendations for the Alzheimer’s drug lecanemab, which is now approved for patients with mild cognitive impairment or mild dementia. The guidance details eligibility including genetic testing for the APOE4 gene, and a strict monitoring schedule with regular brain scans to manage potential side effects.
Source →
•
A new study on migraines found that emergency department visits are influenced by both acute environmental triggers and longer-term factors. These findings could help patients and doctors identify and manage the specific triggers that lead to severe migraine attacks requiring emergency care.
Source →
•
A promising new antiviral drug, ARN-75039, has been shown to provide therapeutic protection against Lassa virus infection in guinea pigs. This development is a significant step toward a potential treatment for this severe and often fatal viral disease.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
